Biodexa Pharmaceuticals (BDRX) Competitors $8.34 +0.23 (+2.84%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$8.39 +0.05 (+0.59%) As of 07:30 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock BDRX vs. BLRX, THAR, AIMD, ASBP, PCSA, LPCN, PULM, NRSN, NAII, and MTEXShould you be buying Biodexa Pharmaceuticals stock or one of its competitors? The main competitors of Biodexa Pharmaceuticals include BioLineRx (BLRX), Tharimmune (THAR), Ainos (AIMD), Aspire Biopharma (ASBP), Heatwurx (PCSA), Lipocine (LPCN), Pulmatrix (PULM), NeuroSense Therapeutics (NRSN), Natural Alternatives International (NAII), and Mannatech (MTEX). These companies are all part of the "pharmaceutical products" industry. Biodexa Pharmaceuticals vs. Its Competitors BioLineRx Tharimmune Ainos Aspire Biopharma Heatwurx Lipocine Pulmatrix NeuroSense Therapeutics Natural Alternatives International Mannatech BioLineRx (NASDAQ:BLRX) and Biodexa Pharmaceuticals (NASDAQ:BDRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, earnings, analyst recommendations, institutional ownership, valuation, dividends and profitability. Which has higher valuation & earnings, BLRX or BDRX? Biodexa Pharmaceuticals has lower revenue, but higher earnings than BioLineRx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioLineRx$28.94M0.58-$9.22M-$8.80-0.43Biodexa Pharmaceuticals$470K11.00-$7.32MN/AN/A Do insiders & institutionals have more ownership in BLRX or BDRX? 1.6% of BioLineRx shares are held by institutional investors. Comparatively, 17.5% of Biodexa Pharmaceuticals shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 0.3% of Biodexa Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate BLRX or BDRX? BioLineRx presently has a consensus price target of $26.00, suggesting a potential upside of 579.56%. Given BioLineRx's stronger consensus rating and higher possible upside, equities analysts plainly believe BioLineRx is more favorable than Biodexa Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioLineRx 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67Biodexa Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Is BLRX or BDRX more profitable? Biodexa Pharmaceuticals has a net margin of 0.00% compared to BioLineRx's net margin of -45.34%. Biodexa Pharmaceuticals' return on equity of 0.00% beat BioLineRx's return on equity.Company Net Margins Return on Equity Return on Assets BioLineRx-45.34% -49.74% -17.54% Biodexa Pharmaceuticals N/A N/A N/A Does the media refer more to BLRX or BDRX? In the previous week, Biodexa Pharmaceuticals had 3 more articles in the media than BioLineRx. MarketBeat recorded 3 mentions for Biodexa Pharmaceuticals and 0 mentions for BioLineRx. BioLineRx's average media sentiment score of 1.89 beat Biodexa Pharmaceuticals' score of 0.72 indicating that BioLineRx is being referred to more favorably in the media. Company Overall Sentiment BioLineRx Very Positive Biodexa Pharmaceuticals Positive Which has more volatility and risk, BLRX or BDRX? BioLineRx has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500. Comparatively, Biodexa Pharmaceuticals has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. SummaryBioLineRx beats Biodexa Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BDRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BDRX vs. The Competition Export to ExcelMetricBiodexa PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.02M$3.41B$6.08B$10.55BDividend YieldN/A2.29%5.73%4.78%P/E RatioN/A23.0784.5627.19Price / Sales11.00486.15596.76132.96Price / CashN/A46.9737.8662.13Price / Book2.8710.5012.386.65Net Income-$7.32M-$52.47M$3.32B$276.79M7 Day Performance-9.25%2.90%2.25%1.75%1 Month Performance22.65%15.36%9.62%5.15%1 Year Performance-85.79%14.29%73.83%36.96% Biodexa Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BDRXBiodexa Pharmaceuticals0.7098 of 5 stars$8.34+2.8%N/A-90.1%$5.02M$470K0.0020News CoverageAnalyst ForecastShort Interest ↓Gap DownBLRXBioLineRx2.3682 of 5 stars$4.31+2.0%$26.00+503.9%-79.6%$18.34M$28.94M-0.4940THARTharimmune1.91 of 5 stars$3.05+0.5%$17.00+458.3%+15.2%$17.99MN/A-0.502Short Interest ↑Gap DownAIMDAinos1.4422 of 5 stars$3.84-0.5%N/A+53.3%$17.89M$110.87K-0.7740Analyst ForecastASBPAspire BiopharmaN/A$0.36-7.0%N/AN/A$17.72MN/A0.00N/APositive NewsShort Interest ↓PCSAHeatwurx2.7959 of 5 stars$0.35+26.5%$1.00+183.3%-72.7%$17.47MN/A-0.1520Short Interest ↑Gap DownHigh Trading VolumeLPCNLipocine2.4772 of 5 stars$3.20+0.0%$8.00+149.9%-39.4%$17.35M$11.20M-3.6810PULMPulmatrix0.3745 of 5 stars$4.72-6.8%N/A+117.8%$17.21M$369K-2.1720News CoveragePositive NewsEarnings ReportShort Interest ↑NRSNNeuroSense Therapeutics3.3553 of 5 stars$1.15-1.7%$14.00+1,117.4%+24.6%$17.08MN/A-2.1310News CoverageAnalyst UpgradeShort Interest ↓Analyst RevisionNAIINatural Alternatives International1.6187 of 5 stars$2.75-0.4%N/A-41.6%$17.00M$129.86M-1.21290Short Interest ↓Gap UpHigh Trading VolumeMTEXMannatech0.4988 of 5 stars$8.91-1.1%N/A+10.9%$16.93M$112.98M-4.37250 Related Companies and Tools Related Companies BioLineRx Competitors Tharimmune Competitors Ainos Competitors Aspire Biopharma Competitors Heatwurx Competitors Lipocine Competitors Pulmatrix Competitors NeuroSense Therapeutics Competitors Natural Alternatives International Competitors Mannatech Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BDRX) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals PLC Unsponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
